Abstract:Presently, a significant number of pharmaceutical drugs exhibit poor solubility in water and fall within categories II and IV of the biopharmaceutical classification system. This predicament has prompted the exploration for novel solvents or excipients to enhance the solubility and bioavailability of the active compounds in aqueous environments. Low-melting mixture solvents (LoMMSs) have gained recognition as potential solvents for active pharmaceutical ingredients to improve therapeutic efficacy and delivery. This study focuses on the preparation of a eutectic mixture composed of betaine, malic acid, proline, and water (BE-MA-PR-WA) to enhance the formulation options for tolvaptan, an FDA-approved medication used to treat acute congestive heart failure, which has limited solubility in aqueous solutions. The findings presented in this article represent the first reported results on the administration of LoMMS-solubilized tolvaptan. Furthermore, an examination of the solubility and bioavailability of tolvaptan utilizing this mixture was conducted, alongside an assessment of its toxicity. The solubility of tolvaptan in BE-MA-PR-WA (1:1:1:7) increased 483 times compared to solubility in water. Toxicity studies indicated that the LoMMS formulation BE-MA-PR-WA was safe for oral administration. The oral bioavailability of tolvaptan was significantly increased by 1.9-fold in the BE-MA-PR-WA than that in water. In addition, the 5-hour urine volume of rats indicated that BE-MA-PR-WA also enhanced the diuretic effects of tolvaptan in rats. The findings suggest that BE-MA-PR-WA enhance the solubility and bioavailability of tolvaptan, and are deemed non-toxic. Consequently, LoMMS may be deemed promising solubilizing agents, potentially facilitating the absorption of poorly bioavailable medications.

Pharmaceutical salt and salt hydrates of vortioxetine with sulfonic acid to ameliorate the solubility and hygroscopicity via the charge-assisted hydrogen bond assembly

Salt or/and cocrystal? The case of the antidepressant drug venlafaxine

Diaqua(2,2′-diamino-4,4′-bi-1,3-thiazole)oxosulfatovanadium(IV) Tetrahydrate

Preparation and Stability Research of Tenofoviral Afenamide D-(-)-Tartaric Acid Salt (2 ∶ 1)

Discovered two polymorphs and two solvates of lamotrigine-tolfenamic acid salt: Thermal behavior and crystal morphological differences

Preparation, characterization, and crystal structures of novel sophocarpine salts with improvements on stability and solubility

Amino Acids As Co-Amorphous Excipients for Tackling the Poor Aqueous Solubility of Valsartan.

A New Strategy to Design Isostructural Salts: the Case of the Antitumor Drug Dimethylaminomicheliolide

Structural Characterization and Pharmaceutical Evaluation of Telmisartan Hydrochloride Salts

Bromhexine and its fumarate salt: Crystal structures, Hirshfeld surfaces and dissolution study

A series of stable, metastable and unstable salts of Imatinib with improved solubility

Pharmaceutical Salts of Haloperidol with Some Carboxylic Acids and Artificial Sweeteners: Hydrate Formation, Polymorphism, and Physicochemical Properties

Investigation into the structures and physicochemical properties of multi-component crystals of voriconazole

Novel Pharmaceutical Cocrystal of Voxelotor, a Hemoglobin Oxygen Affinity Modulator: Synthesis, Crystal Structure, and Physicochemical Properties

Torsemide Crystalline Salts with a Significant Spring-Parachute Effect

Structural analysis and properties of three novel sulfonic acid-based pharmaceutical salts of paliperidone

Twelve Salts Fabricated from 2-amino-5-methylthiazole and Carboxylic Acids through Combination of Classical H-bonds and Weak Noncovalent Associations

Salts of 2-hydroxybenzylamine with improvements on solubility and stability: Virtual and experimental screening

Improving Solubility and Avoiding Hygroscopicity of Tetrahydropalmatine by Forming a Pharmaceutical Salt Cocrystal via CAHBs

X-ray structure and conformational study of tris(2-(dimethylamino)phenyl)methanol salt derivatives: Roles of anions and hydrogen bond

Low-melting mixture solvents as novel solubilizing agents: Improving tolvaptan formulation and therapeutic efficacy